Advanced Filters
noise
Found 387 clinical trials

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.

18 - 75 years of age Female Phase 1/2
X Xinchen Wang, Dr.

Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

The goal of this clinical trial is to evaluate the efficacy and safety of Socazolimab combined with chemotherapy with or without bevacizumab as first-Line treatment in persistent, recurrent, or metastatic cervical cancer. The main question it aims to answer is: Does Socazolimab combined with chemotherapy with or without bevacizumab better …

18 - 75 years of age Female Phase 3
M M Jalving, MD, PhD

Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

This is a nationwide, multicenter, registry-based prospective cohort study to assess real-world effectiveness of treatment with a pembrolizumab containing regimen in persistent, recurrent, or metastatic cervical cancer. Patients in the observation cohort continue treatment according to standard of care. In the discontinuation cohort, patients discontinue their maintenance treatment with pembrolizumab …

18 years of age Female Phase 4
L Lung-Ji Chang, Ph.D

Engineered Immune Effectors Against Cervical Cancer

The primary objective of this study is to evaluate the safety of cervical cancer specific engineered immune effectors (CC-EIEs). The secondary objectives are to evaluate the rate of successful CC-EIE generation in vitro and determine the anti-CC efficacy.

10 - 80 years of age Female Phase 1/2
L Lung-Ji Chang, Ph.D

Intervention of CAR-T Against Cervical Cancer

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer. Another goal of the study is to learn more about the persistence and function of CAR T …

18 - 70 years of age Female Phase 1/2
Y Yuanming Shen, Dr

Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial

Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.

18 - 70 years of age Female Phase 2
A Anissa Megzari

Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer

Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.

18 years of age Female Phase N/A
B Beau Abar, PHD MS

Emergency Department-based Cervical Cancer Screening Through Self-sampling

This project will compare the uptake of cervical cancer screening through ED HPV sampling among patients presenting to the ED.

30 - 65 years of age Female Phase N/A
J Junyun Li, M.D

Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial

Evaluate the efficacy and safety of neoadjuvant chemotherapy (NAC) with albumin-bound paclitaxel and carboplatin followed by chemoradiation therapy (CRT) for stage IIIC cervical cancer patients with carcinoma \>4 cm in greatest dimension and/or lymph node \>2cm in short axis.

18 - 70 years of age Female Phase 3
J Jing Chen

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

This study is an exploratory clinical trial to investigate the feasibility of neoadjuvant chemoimmunotherapy plus extrafascial hysterectomy and pelvic lymph node dissection in patients with stage IB2 (2018 FIGO) cervical cancer and to observe the response rate to treatment, adverse effects and complications, and to assess the survival rate of …

18 - 70 years of age Female Phase 2

Simplify language using AI